Obtenga las últimas noticias sobre las acciones de Veru con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de VERU

Últimas noticias sobre

VERU INC

Veru

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Veru Inc

VERUS INTL INC by Verus International, Inc.

Verus International Inc

VerusCoin

News

Press Releases

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

General

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

Veru to Participate in the Virtual BTIG Obesity Health Forum

Health Care

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

Veru Announces Reverse Stock Split

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology

Earnings

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

VERU

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

CalciMedica

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Durect

Grace Therapeutics

Hyperion DeFi

IGC Pharma

Iterum Therapeutics

Incannex Healthcare

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

NRX Pharmaceuticals

Nasus Pharma

Nutriband

PolyPid

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

SCYNEXIS

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Comments

Veru Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL